Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC

Phase I Trial of Anti-CS1 Monoclonal Antibody Elotuzumab in Combination With Bortezomib in the Treatment of Relapsed/Refractory Multiple Myeloma

(2012) Andrzej J. Jakubowiak et al.   JOURNAL OF CLINICAL ONCOLOGY

Elotuzumab in Combination With Lenalidomide and Low-Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma

(2012) Sagar Lonial et al.   JOURNAL OF CLINICAL ONCOLOGY

A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma

(2011) J. A. Zonder et al.   BLOOD

IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect

(2011) D. M. Benson et al.   BLOOD

Monoclonal antibodies in the treatment of multiple myeloma

(2011) Paul G. Richardson et al.   BRITISH JOURNAL OF HAEMATOLOGY

Rationale and efficacy of interleukin-1 targeting in Erdheim-Chester disease

(2010) A. Aouba et al.   BLOOD

The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody

(2010) D. M. Benson et al.   BLOOD

Monoclonal antibodies for cancer immunotherapy

(2009) Louis M Weiner et al.   LANCET

Influence of CRACC, a SLAM family receptor coupled to the adaptor EAT-2, on natural killer cell function

(2009) Mario-Ernesto Cruz-Munoz et al.   NATURE IMMUNOLOGY

Stem cell factor and interleukin-2/15 combine to enhance MAPK-mediated proliferation of human natural killer cells

(2008) D. M. Benson et al.   BLOOD

Activation of extracellular signaling regulated kinase in natural killer cells and monocytes following IL-2 stimulation in vitro and in patients undergoing IL-2 immunotherapy: analysis via dual parameter flow-cytometric assay

(2008) Sri Vidya Kondadasula et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

CS1, a Potential New Therapeutic Antibody Target for the Treatment of Multiple Myeloma

(2008) E. D. Hsi et al.   CLINICAL CANCER RESEARCH

Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu

(2007) Y.-T. Tai et al.   BLOOD